Mortality in Staphylococcus aureus bacteraemia remains high despite adherence to quality indicators: secondary analysis of a prospective cohort study
- PMID: 34626700
- DOI: 10.1016/j.jinf.2021.10.001
Mortality in Staphylococcus aureus bacteraemia remains high despite adherence to quality indicators: secondary analysis of a prospective cohort study
Abstract
Objectives: To evaluate the association between compliance with previously published quality indicators (QIs) for the management of Staphylococcus aureus bacteraemia (SAB) and 30-day mortality.
Methods: We conducted a post hoc analysis of all adult patients with SAB who were hospitalized at a Spanish university hospital between 2013 and 2018. We evaluated the compliance with 7 QIs of SAB management (i.e., Infectious Diseases consultation, follow-up blood cultures, early source control, echocardiography, early cloxacillin or cefazolin, vancomycin monitoring, and appropriate treatment duration). The QIs compliance rate was considered good if ≥75% of the QIs recommended in each patient were performed. We studied the impact of different risk factors (including QIs compliance) on 30-day all-cause mortality adjusting by multivariable modeling and propensity-matched analysis.
Results: We included 441 patients with SAB. The QIs compliance rate was ≥75% in 361 patients (81.9%). A total of 95 patients (21.5%) died within 30 days after the index blood culture. In the multivariable model, the variables associated with 30-day mortality were: age (OR, 1.1; 95% CI, 1.0-1.1), Charlson comorbidity index (OR, 1.2; 95% CI, 1.1-1.4), persistent bacteraemia >72 h (OR, 6.0; 95% CI, 3.2-11.5), infective endocarditis (OR, 2.8; 95% CI, 1.2-6.7), and SAB of unknown source (OR, 3.3; 95% CI, 1.5-7.1). We did not find an association between a global QIs compliance rate of ≥75% or any individual QI with 30-day mortality.
Conclusions: SAB 30-day mortality remains high despite good adherence to previously published QIs for the management of SAB. Future research should focus on additional factors to further improve SAB-related mortality.
Keywords: Bacteraemia; Clinical management; Mortality; Quality indicators; S. aureus.
Copyright © 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest All authors: No reported conflicts of interest. All authors have submitted the ICMJE form for disclosure of potential conflicts of interest.
Comment in
-
Significantly lower 30 day/inpatient mortality observed in people who inject drugs (PWID) compared to non-PWID with Staphylococcus aureus bacteraemia.J Infect. 2022 Oct;85(4):436-480. doi: 10.1016/j.jinf.2022.06.010. Epub 2022 Jun 18. J Infect. 2022. PMID: 35724756 No abstract available.
Similar articles
-
Development of quality indicators for the management of Staphylococcus aureus bacteraemia.J Antimicrob Chemother. 2019 Nov 1;74(11):3344-3351. doi: 10.1093/jac/dkz342. J Antimicrob Chemother. 2019. PMID: 31393551 Free PMC article.
-
Adherence to and clinical utility of "quality indicators" for Staphylococcus aureus bacteremia: a retrospective, multicenter study.Infection. 2024 Aug;52(4):1527-1538. doi: 10.1007/s15010-024-02284-z. Epub 2024 May 10. Infection. 2024. PMID: 38727926 Free PMC article.
-
Adherence to standards of care and mortality in the management of Staphylococcus aureus bacteraemia in Peru: A prospective cohort study.Int J Infect Dis. 2020 Jul;96:601-606. doi: 10.1016/j.ijid.2020.06.002. Epub 2020 Jun 4. Int J Infect Dis. 2020. PMID: 32505877
-
Diagnosis and management of Staphylococcus aureus bacteraemia.Intern Med J. 2005 Dec;35 Suppl 2:S17-24. doi: 10.1111/j.1444-0903.2005.00977.x. Intern Med J. 2005. PMID: 16271058 Review.
-
Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia.Clin Microbiol Infect. 2019 Jul;25(7):818-827. doi: 10.1016/j.cmi.2019.03.010. Epub 2019 Mar 27. Clin Microbiol Infect. 2019. PMID: 30928559
Cited by
-
Staphylococcus aureus bacteraemia and mortality: a population-based study in Olmsted County, Minnesota, from 2006 to 2020.Infect Dis (Lond). 2023 Jan;55(1):1-8. doi: 10.1080/23744235.2022.2123561. Epub 2022 Sep 24. Infect Dis (Lond). 2023. PMID: 36151989 Free PMC article.
-
Genetic Testing Technology Assisting in the Diagnosis and Treatment of Multiple Suppurative Arthritis and Extensive Migratory Skin and Soft Tissue Infections Caused by Disseminated Staphylococcus aureus Disease: A Case Report and Review.Infect Drug Resist. 2024 Sep 25;17:4185-4194. doi: 10.2147/IDR.S479043. eCollection 2024. Infect Drug Resist. 2024. PMID: 39347491 Free PMC article.
-
Adherence to Staphylococcus aureus Bacteremia Management Recommendations Before, During, and After the COVID-19 Pandemic: Prognostic Implications.Antibiotics (Basel). 2025 Jun 18;14(6):615. doi: 10.3390/antibiotics14060615. Antibiotics (Basel). 2025. PMID: 40558205 Free PMC article.
-
The LAUsanne STAPHylococcus aureus ENdocarditis (LAUSTAPHEN) score: A prediction score to estimate initial risk for infective endocarditis in patients with S. aureus bacteremia.Front Cardiovasc Med. 2022 Dec 9;9:961579. doi: 10.3389/fcvm.2022.961579. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36568565 Free PMC article.
-
Design, synthesis, and evaluation of 1,4-benzothiazine-3-one containing bisamide derivatives as dual inhibitors of Staphylococcus aureus with plausible application in a urinary catheter.Front Chem. 2024 Jun 26;12:1420593. doi: 10.3389/fchem.2024.1420593. eCollection 2024. Front Chem. 2024. PMID: 38988728 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical